Epstein-Barr virus: biology, pathogenesis and therapy of lymphomas
Open Access
- 24 November 2025
- journal article
- review article
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 2154
Abstract
Epstein-Barr virus (EBV) remains dormant in host B cells for a long time, and more than 90% of patients are asymptomatically infected. However, some internal factors (such as immune deficiency) or exogenous factors (such as HIV infection, inflammation and hypoxia) can destroy this underlying property and lead to disease development. EBV was originally discovered in association with Burkitt lymphomas and is now etiologically associated with malignant lymphomas of B, T, and NK cell origins. Previous relevant studies have reported that EBV could promote the occurrence and development of lymphomas and affect the prognosis. In fact, the pathogenesis of EBV-associated lymphomas involves different viral gene expression patterns and complex cytogenetic changes. Here, the present study summarizes viral two life cycles, latent modes, the establishment of latency and viral reactivation. We also focus on the occurrence of EBV-related lymphomas, generalize and put forward novel perspectives or innovative solutions for treatments according to these pathogenic mechanisms.Keywords
Funding Information
- National Natural Science Foundation of China (No. 81974426)
- Chen Xiao-Ping Foundation for the Development of Science and Technology of Hubei Province (No. CXPJJH124010-050)
- Hubei Provincial Society of Pathophysiology (No.2025HBAP022)
This publication has 153 references indexed in Scilit:
- EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2024
- EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2022
- The BCL‐2 family protein inhibitor ABT‐737 as an additional tool for the treatment of EBV‐associated post‐transplant lymphoproliferative disordersMolecular Oncology, 2020
- Frequency and clinical correlates of elevated plasma Epstein‐Barr virus DNA at diagnosis in peripheral T‐cell lymphomasInternational Journal of Cancer, 2016
- Response to 5‐azacytidine in a patient with TET2‐mutated angioimmunoblastic T‐cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV‐positive large B‐cell lymphomaHematological Oncology, 2016
- Modes of infection and oncogenesis by the Epstein–Barr virusReviews in Medical Virology, 2014
- Switching of EBV cycles between latent and lytic statesReviews in Medical Virology, 2013
- Epstein–Barr virus (EBV) association and latency profile in pediatric Burkitt's lymphoma: Experience of a single institution in ArgentinaJournal of Medical Virology, 2013
- Suppression of the LMP2A target gene, EGR‐1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycleThe Journal of Pathology, 2013
- Epstein‐Barr virus and the pathogenesis of Burkitt's lymphoma: More questions than answersInternational Journal of Cancer, 2009